Henry Schein stock gains on earnings outlook upgrade

Henry Schein stock (ISIN US42548G1040) is trading close to its recent highs as of September 16, 2026, supported by an upgraded earnings outlook that has lifted the shares’ appeal for some investors. According to Zacks on September 16, 2026, the stock has been raised to a Zacks Rank 2 (Buy) as analysts modestly lift their profit estimates for the current fiscal year.

Analysts lift estimates for fiscal 2026

According to Zacks on September 16, 2026, Henry Schein is expected to earn USD 5.36 per share in fiscal year 2026, essentially unchanged versus the prior year’s reported EPS. Over the past three months, the Zacks Consensus Estimate for the company has increased by 0.8 percent, a small but notable upward revision that underpins the rating upgrade to Rank 2 (Buy).

The Zacks analysis highlights that Henry Schein’s earnings estimate revisions place the stock in the top 20 percent of its coverage universe in terms of positive changes to forecasts. According to Zacks, this pattern of upward revisions is often a key driver of future share price performance as investors respond to improving profit expectations.

Recent growth trends and valuation context

Beyond the estimate revisions, third-party commentary points to a gradual improvement in Henry Schein’s growth profile. An article on September 16, 2026 notes that the company’s results for the second quarter of 2026 challenge the perception of it being a purely slow-growing distributor, pointing to better growth momentum in its core business segments, even as valuation metrics remain relatively undemanding. As Seeking Alpha discusses in its September 16, 2026 analysis, Henry Schein’s improving revenue growth has not yet fully translated into a higher valuation multiple, which some investors see as an opportunity.

According to Yahoo Finance on September 16, 2026, Henry Schein’s earnings outlook upgrade reflects confidence that its health care products and services franchise can deliver steady profits in the face of broader market volatility. The report reiterates the expectation for fiscal 2026 EPS of USD 5.36 and emphasizes that analysts have become slightly more optimistic in recent months, with the consensus estimate rising 0.8 percent compared with earlier projections.

Stock level and market metrics

On the market side, Henry Schein stock is quoted on Nasdaq under the ticker HSIC. A recent price snapshot shows the shares changing hands at USD 86.77 on Nasdaq, with the session on September 16, 2026 seeing an intraday low of USD 86.44 and a high of USD 88.32, and trading volume around 1,020,000 shares versus an average daily volume near 924,500 shares. These figures imply that the current price is 0.4 percent above the day’s low and 1.8 percent below the day’s high, placing the stock relatively close to the top of its intraday range as of that date.

With the stock at USD 86.77 on Nasdaq as of September 16, 2026, Henry Schein’s market capitalization stands at approximately USD 9.67 billion. The shares trade at a price-to-earnings multiple of 25.50 based on trailing earnings, which investors can compare with sector peers to gauge whether the valuation appropriately reflects the company’s growth prospects and the stability of its dental and medical distribution businesses.

Operational backdrop and risk considerations

Operationally, Henry Schein continues to balance growth initiatives with quality control responsibilities. As Simply Wall St notes in a September 17, 2026 commentary, the company has expanded access to advanced laboratory testing technologies through distribution agreements for high-throughput molecular diagnostics platforms, while also managing voluntary recalls of certain dental products due to packaging and instruction issues. This mix of expansion and recall-related work underscores both Henry Schein’s growth ambitions and its exposure to regulatory and quality risks in clinical markets.

For investors, this context means that the improved earnings outlook and modest upward estimate revisions need to be weighed against ongoing operational challenges. Expanded technology offerings can strengthen long-term revenue streams, but product recall obligations and regulatory oversight can add costs or reputational pressures. The current valuation, with a trailing P/E ratio around 25.50 and a market capitalization near USD 9.67 billion, suggests that the market prices in steady, not explosive, growth while acknowledging these risks.

Stock price as of the latest session

As of September 16, 2026, Henry Schein stock closed at USD 86.77 on Nasdaq, with the trading range between USD 86.44 and USD 88.32 on that day and a volume of about 1,020,000 shares. This places the shares at a level that reflects the recent earnings estimate upgrades and the company’s balanced profile of growth initiatives and quality-control responsibilities, giving investors a reference point for assessing whether the stock’s current valuation aligns with their own expectations for fiscal year 2026 and beyond.

More news and analyses on Henry Schein stock